DESTINY-Gastric01 trial: what clinicians have said so far
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
- NCT03329690 ↗
- Completed
- Daiichi Sankyo Co., Ltd.
- Deep size, estimated: 301+ verified statements once built
We haven't built an HCP commentary report on DESTINY-Gastric01 (trastuzumab deruxtecan in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 40 most recent indexed sources
Automated from the 40 newest of 142 indexed sources (Oct 2021 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether HER2 status must be re-biopsied after trastuzumab progression before starting T-DXd
- Whether T-DXd has meaningful activity in HER2-low IHC 2+/ISH− or IHC 1+ gastric cancer
- Whether findings from an East Asian third-line population apply to Western patients
- Whether baseline HER2 level and MET, EGFR or FGFR2 alterations predict response to T-DXd
Indexed commentary on DESTINY-Gastric01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 62 YouTube videos, typically up to 273 once built | |
| 43 posts on X, typically up to 189 once built | |
| 37 podcast episodes, typically up to 163 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Neoplasm, Gastrointestinal
- Interventions
- DS-8201a; Physician's Choice
- Arms
- Parallel: DS-8201a · Experimental
- Parallel: Physician's Choice · Active comparator
- Exploratory: Naïve HER2 IHC 2+/ISH- · Other
- Exploratory: Naïve HER2 IHC 1+ · Other
- Enrollment
- 233
- Primary outcomes
- Percentage of Participants With Objective Response Rate Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)
- Percentage of Participants With Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)
- Sponsor
- Daiichi Sankyo Co., Ltd. with AstraZeneca
- Start
- Nov 2, 2017
- Primary completion
- Nov 8, 2019
- Results posted
- Yes
- Registry record
- NCT03329690 · updated Mar 18, 2022
Publications
linked from the registry- Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. PubMed 32469182
- Kapil A, Failmezger H, Fu Y, Spitzmuller A, Chan J, Haneder S, Shumilov A, Barkell A, Oguma T, Inaki K, Suto F, Allard J, Lee J, Lambert AW, Schick M, Barrett JC, Schmidt G, Sade H, Gustavson M, Carroll D, Cecchi F. Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer. JCO Precis Oncol. 2026 May;10(5):e2500823. doi: 10.1200/PO-25-00823. Epub 2026 May 28. PubMed 42208007
- Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Shimoyama T, Lee KW, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Shitara K. Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial. J Clin Oncol. 2023 Feb 1;41(4):816-825. doi: 10.1200/JCO.22.00575. Epub 2022 Nov 15. PubMed 36379002